[Comparative efficacy of betaserc and cinnarizine of vertigo in patients with migraine].
Headache and vertigo often emerge simultaneously. Fifty six (40%) out of 140 patients complaining of vertigo were studied. Emerging in the aura and/or in headache phases, vertigo was more frequently registered in patients suffered from migraine with aura (57%). Vertigo associated with migraine was diagnosed in 25% of the cases. The patients were randomized into 2 equal identical groups, one of which was treated by betaserc (16 mg, 3 times daily before meal) and the other one was given cinnarizine (25 mg, 3 times daily). Treatment duration was 12 weeks. Reduction of vertigo attacks frequency and headache by 50% and over, in comparison to the baseline period, was considered as beneficial. Fifty three (95%) patients completed the treatment course. Decrease of a risk for negative results and a frequency of positive effect of vertigo therapy were significantly higher in the group receiving betaserc. Reduction of monthly relapses by 50% and over was detected in 79% of the patients of betaserc group and in 52% of those of cinnarizine one. Migraine attacks monthly frequency was diminished by 43% and 64%, respectively. Therefore, betaserc is considered for using as vertigolytic medication and for migraine attacks prevention.
Amelin
A V
AV
Skoromets
A A
AA
Gonchar
M A
MA
Tumelevich
B Ch
BCh
Nikitin
K A
KA
D000328:Adult; D000704:Analysis of Variance; D001621:Betahistine / Q000627:therapeutic use*; D002936:Cinnarizine / Q000627:therapeutic use*; D005260:Female; D018494:Histamine Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications*; D016896:Treatment Outcome; D014717:Vertigo / Q000150:complications / Q000188:drug therapy*
D018494:Histamine Agents; D002936:Cinnarizine; D001621:Betahistine